Stone GW, Kimura T, Gao R, et al. - Via an individual patient data pooled analysis and summary-level meta-analysis of four randomized clinical trials of a polymeric bioresorbable scaffold and a contemporary metallic drug-eluting stent in 3,884 individuals, researchers analyzed outcomes of the first-generation bioresorbable vascular scaffold (BVS) prior to and following 3 years, the point of its entire bioresorption in animals. Treatment with BVS vs everolimus-eluting stents (EES) through a 5-year follow-up, was correlated with greater rates of target lesion failure and device thrombosis. Between 0 to 3 years and 3 to 5 years, target lesion failure occurred in 11.6% vs 7.9% and 4.3% vs 4.5% of BVS-treated and EES-treated patients, and device thrombosis occurred in 2.4% vs 0.6% and 0.1% vs 0.3% of BVS-treated and EES-treated patients, respectively. Hence, for the first-generation Absorb BVS, the period of excess risk ends at 3 years. These data give mechanistic perspicacity into the timing of adverse events following BVS and for patients with coronary artery disease and for bioresorbable technology to be taken as a legitimate alternative, it helps to recognize the obstacles to overcome.